Train Your Recovery: Why Bouncing Back May Matter More Than Your Biological Age Score

News
#1

RecoveryAsAgingMeasure-2
RecoveryAsAgingMeasure-22752×1536 426 KB

Researchers from Swedish Medical Center and the University of Denver argue that aging is best understood as a progressive loss of “biological self-correction”: the body’s ability to sense a disturbance, mount a proportionate response, repair damage, switch the response off and recover while keeping reserve for the next challenge. Rather than replacing the hallmarks of aging, the framework treats them as candidate mechanisms behind impaired recovery. The authors propose measuring aging dynamically, by tracking how people respond to and recover from standardized stressors such as exercise, vaccination or a glucose challenge, instead of relying only on resting biomarkers like epigenetic clocks. They rank longevity interventions by evidence, placing exercise and cardiometabolic control at the top and NAD+ precursors, senolytics and partial reprogramming well below.

A thermostat is judged not by the temperature in a quiet room but by how well it handles an open window. A new review argues that human aging should be judged the same way.

David Bar-Or and colleagues, writing in the journal Geriatrics, propose that aging is fundamentally a decline in “biological self-correction.” Young bodies take constant damage too, they note, but they detect it quickly, respond in proportion, repair it and then switch the response off. With age, each step can falter. Responses come late or overshoot. Repairs are incomplete. Inflammation that should end keeps smoldering. And sometimes the body settles efficiently into a worse equilibrium, such as chronically raised inflammation or blood pressure, and then defends that state as if it were normal.

This view does not discard the familiar hallmarks of aging, such as DNA damage, failing protein quality control, dysfunctional mitochondria and senescent cells. Instead it treats them as possible reasons the correction cycle breaks down. Senescence, for example, starts as a sensible defense against cancer but becomes harmful when the immune system stops clearing the arrested cells.

The practical proposal is a shift in measurement. Rather than reading biological age from a single blood draw, researchers would apply a defined stress, such as an exercise test, a vaccine or a sugary drink, and track the response over time: how far function drops, how quickly it returns, what it costs and whether reserve remains for the next challenge. The authors list ten or more trajectory features to capture.

The review is also notably sober about popular longevity strategies. NAD+ precursors reliably raise NAD+ levels in blood but have not consistently improved function in human trials. Senolytics remain preliminary in people. Partial reprogramming is still a laboratory tool with cancer risks. Even mTOR inhibition is framed carefully: the authors suggest healthy aging may depend on switching flexibly between growth and maintenance modes rather than keeping growth signaling permanently low (a position that is well known in the Longevity / rapamycin user community already).

At the top of their evidence ranking sit unglamorous interventions: physical activity, resistance training, not smoking, blood pressure and metabolic control, vaccination, sleep and diet. Exercise gets special emphasis because it is both a controlled stress and a way of training the body’s response to stress.

The weaknesses are real. The paper presents no new data, and its literature search was not systematic. The authors acknowledge that “self-correction” overlaps heavily with existing ideas such as resilience, allostasis and physiological reserve. More importantly, the review omits a body of work that has already measured recovery dynamics in humans, including analyses of blood markers showing that recovery from fluctuations slows with age. With so many possible stressors, readouts and trajectory measures, and an escape clause for “defended” unhealthy setpoints, the framework may be harder to falsify than the authors suggest.

Still, the core idea has value. A clock that reads lower after a supplement means little if you recover no better from illness, surgery or a hard week. Measuring how people bounce back, not just how they look at rest, is a reasonable next step for the field.

Actionable insights

The review generates no new data, so its practical messages rest on the human studies it cites.

  1. Resistance training. In a meta-analysis of cohort studies, any resistance training versus none was linked to 15 percent lower all-cause mortality (Cohen’s d approx. 0.09, small), with the largest reduction, about 26 percent, at roughly 60 minutes per week and no extra benefit beyond. Combining resistance and aerobic activity was linked to 40 percent lower mortality versus doing neither (d approx. 0.28). For a group with 10 percent ten-year mortality, that is about 4 fewer deaths per 100 people. These are observational associations.
  2. Lifestyle base. Adults with five low-risk habits (never smoking, regular activity, healthy weight, good diet, moderate alcohol) had projected life expectancy at age 50 that was 14.0 years longer for women and 12.2 years for men than those with none.
  3. Experimental agents. NAD+ precursors show target engagement without consistent functional benefit; senolytics remain preliminary in humans. Avoid indiscriminate stacking.
  4. Self-tracking. Recovery metrics such as heart rate variability rebound after training or glucose return-to-baseline after meals fit this framework, but none are validated as aging measures.

Context and source

Related Reading:

1 Like
#2

Note, this paper is very similar to what Peter Fedichev, of Gero (in Singapore) has been describing for the past decade

Fedichev’s Gero group has spent a decade on the same core idea: aging as progressive loss of the ability to recover from perturbation. The key difference is that Gero actually measured it.

Most directly comparable

  1. Pyrkov et al., “Longitudinal analysis of blood markers reveals progressive loss of resilience and predicts human lifespan limit,” Nature Communications 12, 2765 (2021). This is the closest empirical counterpart to Bar-Or’s “correction fidelity.” The team tracked fluctuations in a blood-count-derived index (DOSI) in the same people over time. The variability rose roughly linearly with age, explained by a longer recovery time, which the authors treat as an independent biomarker of aging and resilience. That recovery time grew from about 2 weeks to over 8 weeks between ages 40 and 90. Extrapolating, recovery time and variance would diverge at about 120 to 150 years, a complete loss of resilience. This partly tests Bar-Or’s main “falsifiable prediction” five years before it was proposed. nihukbiobank
  2. Avchaciov et al., “Unsupervised learning of aging principles from longitudinal data,” Nature Communications 13, 6529 (2022). It treats aging as complex-system dynamics near a tipping point at the edge of dynamic stability and derives a “dynamic frailty indicator” from mouse blood counts. The authors report that mice lose resilience by about 25 weeks of a roughly 100-week lifespan. The indicator responded to a high-fat diet (accelerated aging) and rapamycin (slowed aging), which speaks to Bar-Or’s call for trajectory metrics that respond to interventions. Unsupervised learning of aging principles from longitudinal data +2
  3. Tarkhov, Denisov & Fedichev, “Aging clocks, entropy, and the limits of age-reversal,” bioRxiv (2022, revised after peer review). This maps onto Bar-Or’s “maladaptive but actively defended setpoint.” The authors propose a thermodynamic biological age that tracks entropy produced, and hence information lost, during aging. It rises with age, drives irreversible drift in physiological state, reduces resilience, and accelerates disease and death risk. The conclusion is less optimistic than Bar-Or’s “restored resilience”: the entropic nature of the drift sets severe limits on age reversal. biorxivbiorxiv

Molecular-level precursors

  1. Kogan, Molodtsov, Menshikov, Shmookler Reis & Fedichev, “Stability analysis of a model gene network links aging, stress resistance, and negligible senescence,” Scientific Reports 5, 13589 (2015). This is the mathematical version of Bar-Or’s repair-versus-damage logic. Gene networks are usually inherently unstable and accumulate regulatory deviations exponentially until death, but if repair systems are effective enough the network stabilizes, keeping damage and mortality constrained over very long times. Stability depends on network connectivity, effective genome size, proteome turnover and DNA repair rate. arxivgenengnews
  2. Podolskiy et al. (with Gladyshev and Shmookler Reis), “Critical dynamics of gene networks is a mechanism behind ageing and Gompertz law,” arXiv preprint (2015, revised 2016). It argues that many features of aging and population mortality emerge from the critical dynamics of gene regulation and metabolism, with the resulting instability producing the Gompertz rise in mortality. arxiv

Intervention-focused follow-up

  1. Perevoshchikova & Fedichev, “Differential Responses of Dynamic and Entropic Aging Factors to Longevity Interventions,” bioRxiv (2024). I could only confirm the title and authors, not the findings. From the title, it addresses Bar-Or’s prediction that different interventions should affect different components of the aging trajectory.

How the two frameworks line up

  • Bar-Or’s “correction fidelity” corresponds to Fedichev’s resilience, measured as recovery rate or autocorrelation time.
  • Bar-Or’s “defended maladaptive setpoint” corresponds to Fedichev’s entropic drift of the state the body stabilizes around.
  • Bar-Or proposes deliberate stressors (exercise, vaccines, glucose challenges). Gero instead reads recovery from the body’s spontaneous fluctuations in routine blood tests and wearables, a cheaper approach that already exists at scale.
  • Fedichev separates a reversible dynamic component from an irreversible entropic one. That distinction is the main thing Bar-Or’s framework lacks, and it matters for anyone expecting interventions to “restore” resilience.

All Gero papers come from a company with a commercial interest in resilience-targeting drugs. Fedichev is a shareholder, which the papers disclose.

Sources:

1 Like